Mable (Neurolytic Healthcare)

About:

Genomics based individualized care for people with neurological conditions.

Website: https://www.trymable.com/

Top Investors: Y Combinator, Creative Destruction Lab (CDL), Initialized Capital, Illumina, Fast Track Malmo

Description:

Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions. The company delivers digitally and genomically-driven medical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction.

Total Funding Amount:

$3.25M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Oxford, Oxfordshire, United Kingdom

Founded Date:

2019-01-01

Contact Email:

r.roth(AT)trymable.com

Founders:

Inna Nicole Thalmann, Roman Rothaermel

Number of Employees:

11-50

Last Funding Date:

2022-07-27

IPO Status:

Private

Industries:

© 2025 bioDAO.ai